Written by the Nuvirox Research Team
Key Points
- A 2023 study found rheumatoid arthritis (RA) patients' immune cells have significantly lower NAD+ than healthy donors, and that deficiency correlated with disease severity.
- In lab dishes, treating those same RA immune cells with nicotinamide riboside (NR) or nicotinamide raised NAD+ back toward healthy-donor levels and reduced inflammatory activity.
- No clinical trial has yet tested whether taking an NAD+ precursor changes RA symptoms, joint damage, or disease activity in actual patients.
Short answer: RA patients show a real, measurable NAD+ deficiency in their immune cells that tracks with how severe their disease is — but no one has yet tested whether correcting that deficiency with a supplement changes how patients actually feel or function. The lab-dish finding is genuinely interesting and worth understanding properly; the leap to "this will help your RA" hasn't been made yet, and we want to be upfront about exactly where that line sits.
What is rheumatoid arthritis, and why would NAD+ matter?
Rheumatoid arthritis is an autoimmune disease in which the immune system attacks joint tissue, driving chronic inflammation that can progressively damage joints and tendons. It affects roughly 1–2% of the US population, more commonly women, and can also affect other organ systems beyond joints in more severe cases. Because immune cell activity is so central to RA, researchers have looked at whether the metabolic fuel those cells run on — NAD+ — is altered in RA patients compared to healthy people. This is part of a broader research trend across autoimmune conditions: immune cells are metabolically demanding, and disruptions in how they generate and use energy have increasingly been implicated in driving the excessive, misdirected inflammation that characterizes autoimmune disease more generally, not just RA specifically.
What the 2023 study actually found
Spanish researchers led by José Manuel Villalba compared immune cells from RA patients to those from healthy donors and found that a key inflammatory signaling gene (IL-6) was roughly 20 times more active in RA patients' cells. They also found significant blood NAD+ deficiencies in RA patients that correlated with disease severity — a novel finding suggesting NAD+ status could eventually serve as a marker of how severe someone's RA is. When the researchers treated RA patients' immune cells directly with nicotinamide riboside or nicotinamide in the lab, NAD+ levels rose back toward healthy-donor levels, with nicotinamide mononucleotide (NMN) showing a more modest effect by comparison.
What this study did not do
This was not a clinical trial. No RA patient in this research took an NAD+ precursor as a treatment; the NR/nicotinamide exposure happened to immune cells isolated in a laboratory setting, not to a person managing joint pain and disease activity day to day. The researchers themselves noted this as an opportunity for future clinical trials — not a completed one.
What the related animal research adds — and doesn't
A separate line of animal research found that a different NAD+-boosting molecule, urolithin A, promoted joint health in a mouse model of arthritis. Urolithin A isn't a direct NAD+ precursor in the same sense as nicotinamide riboside — it's a gut-microbiome-derived compound studied for its effects on mitochondrial quality control (a process called mitophagy) — so this finding, while thematically related, doesn't directly extend to the NR-based supplement category this article is otherwise discussing. As the researchers behind the 2023 immune-cell study put it, no other known studies had at that point tested the benefits of NR, nicotinamide, or NMN specifically against arthritis in a live-animal or human model — meaning the entire evidence base for this specific compound class in RA remains the single immune-cell study described above. That's a narrow evidence base by any standard, and it's worth being direct about that rather than letting adjacent research on differently-mechanism compounds imply a broader, more established connection than currently exists.
What this means if you have RA
RA is a progressive, joint-damaging autoimmune disease with well-established, disease-modifying prescription treatments (DMARDs, biologics) that are proven to slow or halt joint damage — treatments that should not be paused, delayed, or substituted based on early-stage lab research. If you're managing RA, this research is worth discussing with your rheumatologist as an area of active interest, not as grounds to change your current treatment plan. For related NAD+ research in joint conditions, our review of NAD+ and osteoarthritis covers a different (non-autoimmune) joint condition with its own separate evidence base, and NAD+ and lupus covers another autoimmune condition currently in active clinical trials — notably, a registered trial is testing NR specifically in systemic lupus erythematosus, another autoimmune disease with documented immune-cell metabolic dysfunction, which may eventually offer a template for how a similar RA trial could be designed.
FROM NUVIROX
Because of the caveats above, we'd encourage you to read this as general background rather than a treatment plan. If you're curious about the ingredient at the center of this research, here's what's in ours, alongside clinician-routing guidance for anything beyond everyday support:
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol + 50 mg quercetin — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg fenugreek galactomannans to support absorption
- Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
Frequently asked questions
Can NAD+ supplements treat rheumatoid arthritis?
No clinical evidence supports that yet. The relevant finding — reduced NAD+ deficiency in isolated immune cells treated in a lab — has not been tested in actual RA patients as a treatment.
Should I stop my RA medication and try an NAD+ supplement instead?
No. RA has proven, disease-modifying prescription treatments that prevent joint damage. This research doesn't support replacing them, and doing so could allow disease progression to continue unchecked.
Is RA-related NAD+ deficiency the same as normal age-related decline?
The 2023 study found RA-specific deficiency correlating with disease severity, distinct from general aging-related NAD+ decline, though the two may interact.
Will there be a clinical trial testing this in RA patients?
The researchers behind the 2023 study explicitly flagged this as a next step, though as of this writing no such trial has been registered or completed for NR or nicotinamide specifically in RA patients.
Is urolithin A the same as the NAD+ precursor in NAD+ Restore?
No. Urolithin A is a gut-microbiome-derived compound studied for mitochondrial quality control (mitophagy), a different mechanism than nicotinamide riboside, which is a direct NAD+ precursor. They're related in theme but not interchangeable.
Could NAD+ status eventually be used to track RA severity?
The 2023 study's authors suggested measuring blood NAD+ levels might help predict which patients respond better to treatments based on disease severity, though this would need validation in larger, prospective studies before becoming a clinical tool.
The bottom line: this is a real, published, peer-reviewed finding — but it's a cell-culture finding, not a patient-outcome finding. That distinction is the whole story here, and it's worth holding onto if this research comes up in conversation with your care team.
References
- Villalba JM, et al. NAD+ deficiency in rheumatoid arthritis patient immune cells correlates with disease severity; reversed by nicotinamide riboside and nicotinamide treatment. Reported May 2023.
- Ward MM, Guthrie LC, Alba MI. Clinically important changes in Short Form 36 Health Survey Scales for use in rheumatoid arthritis clinical trials. Arthritis Care Res. 2014;66:1783-1789.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.